Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial

There are few studies focus on post-neoadjuvant treatment in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-)/lymph node-positive (LN+) breast cancer, a multi-center, open-label, randomized, controlled phase III trial was conducted to evaluate pathological re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yang, He, Yingjian, Fan, Zhaoqing, Chen, Xue, Liu, Yiqiang, Zhang, Chao, Jiang, Hongchuan, Wang, Xin, Wang, Xiang, Xie, Fei, Wang, Shu, Luo, Bin, Kang, Hua, Wang, Tao, Jiang, Zefei, Yuan, Peng, Xu, Binhe, Xu, Ling, Liu, Yinhua, Li, Jinfeng, Xie, Yuntao, Wang, Tianfeng, Ouyang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284834/
https://www.ncbi.nlm.nih.gov/pubmed/37344451
http://dx.doi.org/10.1038/s41523-023-00553-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284834/
https://www.ncbi.nlm.nih.gov/pubmed/37344451
http://dx.doi.org/10.1038/s41523-023-00553-y

Ejemplares similares